Developing a novel ex vivo platform to support hematopoietic cells and characterize the stem cell niche

Information

  • Research Project
  • 10364610
  • ApplicationId
    10364610
  • Core Project Number
    F30HL154749
  • Full Project Number
    5F30HL154749-02
  • Serial Number
    154749
  • FOA Number
    PA-19-191
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 3 years ago
  • Project End Date
    7/31/2024 - 2 months from now
  • Program Officer Name
    GILLASPY, ALLISON
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    9/6/2021 - 2 years ago

Developing a novel ex vivo platform to support hematopoietic cells and characterize the stem cell niche

PROJECT SUMMARY / ABSTRACT Current culture methods reduce the ability of hematopoietic stem cells (HSCs) to successfully engraft in a host. Emerging gene editing technologies such as CRISPR/Cas9 require time in culture to allow for the correction of disease-causing alleles. There is therefore a need to develop new methods of culturing HSCs. Coculture of HSCs with bone marrow niche cells such as mesenchymal stem cells (MSCs) is one possible solution to problems in HSC culture, as these cells provide factors that support HSCs in vivo. However, MSCs cannot be maintained in culture for extended periods of time and fairly rapidly lose expression of niche factors. Through a screen of candidate transcription factors, our lab identified 5 factors that when transduced together restore niche factor expression and allow for prolonged culture. These factors are Kruppel-like factor 7 (Klf7), Osteoclast stimulating factor (Ostf1), X-box binding protein (XBP1), Interferon regulatory factor 3 (Irf3), and Irf7, which we collectively dubbed the KOXII factors. KOXII-transduced MSCs were able to expand both murine and human funtional HSCs to a much greater extent than mock-transduced MSCs. These cells therefore may be useful in expanding HSCs ex vivo for gene correction. However, there are regulatory barriers to the application of murine cells in human therapeutics. The work proposed here will in part focus on the development and characterization of KOXII-transduced human MSCs. After generating these cells, I will determine if the KOXII factors affect expression of niche factors in human MSCs. I will also use flow cytometry and stem cell xenotransplantation to determine if KOXII-transduced MSCs are more effective at driving HSC expansion than unmodified MSCs. Finally, using CRISPR/Cas9-based gene editing of HSCs derived from patients with sickle cell disease as a model, I will determine if coculture of patient cells with KOXII-transduced MSCs can improve the efficiency of gene editing or increase the yield of properly edited cells over current standard HSC culture methods. In parallel, I will use murine KOXII-transduced MSCs to more closely examine niche signalling by MSCs. As these cells can be cultured in relatively large numbers, they are ideal for proteomic studies. In collaboration with the lab of Jeroen Krijgsveld, I will examine the secretome of these cells in order to identify proteins whose secretion is upregulated by the KOXII factors. Using both in vitro and in vivo assays, I will evaluate the effect of these factors on HSC maintenance and proliferation, with the aim of identifying secreted proteins with previously unappreciated roles in MSC-HSC niche interactions.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    F30
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    51036
  • Indirect Cost Amount
  • Total Cost
    51036
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    839
  • Ed Inst. Type
  • Funding ICs
    NHLBI:51036\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALBERT EINSTEIN COLLEGE OF MEDICINE
  • Organization Department
  • Organization DUNS
    081266487
  • Organization City
    BRONX
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    104611900
  • Organization District
    UNITED STATES